Compare Boston Beer Company Inc (SAM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs Tango Therapeutics Inc. — how do they compare? Boston Beer Company Inc trades at $176.75 (market cap $1.82B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 2.1× Boston Beer Company Inc's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Boston Beer Company Inc for 60 Days and Tango Therapeutics Inc. for 0 Days on average.
| SAM | TNGX | |
|---|---|---|
Market Cap | $1.82B | $3.75B |
Volume | 202,975 | 9,619,106 |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $32.90 |
52-Week Low | $161.08 | $7.50 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | $1.59B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SAM trades at $178.14, up 1.74% today, near resistance at $178. The stock shows a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, 2025 revenue held at $1.96B with net income improving to $108M, yet 2026 guidance projects a net loss. The company is expanding its brand portfolio with new products and marketing initiatives to counter volume declines.
Outlook: SAM faces near-term headwinds from projected 2026 losses and competitive pressure, but brand investments and innovation provide growth avenues. Risks include execution challenges and weak consumer demand. The consensus price target of $204.44 implies potential upside, supported by a debt-free balance sheet, but investor sentiment remains cautious amid earnings misses.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
